Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines

Press Release
February 5, 2024

Download PDF

View next article

Unless otherwise specified, all company and product names appearing in this Website are trademarks owned by or licensed to TerSera Therapeutics LLC, its subsidiaries or affiliates. No use of any TerSera trademark, trade name, or trade dress in this Website may be made without the prior written authorization of TerSera, except to identify the product or services of the company.